Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Protecting stable biological nomenclatural systems enables universal communication: A collective international appeal.
Jiménez-Mejías P, Manzano S, Gowda V, Krell FT, Lin MY, Martín-Bravo S, Martín-Torrijos L, Nieto Feliner G, Mosyakin SL, Naczi RFC, Acedo C, Álvarez I, Crisci JV, Luceño Garcés M, Manning J, Moreno Saiz JC, Muasya AM, Riina R, Meseguer AS, Sánchez-Mata D; 1543 additional coauthors. Jiménez-Mejías P, et al. Bioscience. 2024 Jun 19;74(7):467-472. doi: 10.1093/biosci/biae043. eCollection 2024 Jul. Bioscience. 2024. PMID: 39156614 Free PMC article.
Establishment of head and neck squamous cell carcinoma mouse models for cetuximab resistance and sensitivity.
Zaryouh H, De Pauw I, Baysal H, Melis J, Van den Bossche V, Hermans C, Lau HW, Lambrechts H, Merlin C, Corbet C, Peeters M, Vermorken JB, De Waele J, Lardon F, Wouters A. Zaryouh H, et al. Among authors: melis j. Cancer Drug Resist. 2023 Oct 17;6(4):709-728. doi: 10.20517/cdr.2023.62. eCollection 2023. Cancer Drug Resist. 2023. PMID: 38239393 Free PMC article.
Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer.
Flieswasser T, Van den Eynde A, Freire Boullosa L, Melis J, Hermans C, Merlin C, Lau HW, Van Audenaerde J, Lardon F, Smits E, Pauwels P, Jacobs J. Flieswasser T, et al. Among authors: melis j. Oncoimmunology. 2023 Mar 23;12(1):2192100. doi: 10.1080/2162402X.2023.2192100. eCollection 2023. Oncoimmunology. 2023. PMID: 36970072 Free PMC article.
Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020.
Kooijman JJ, van Riel WE, Dylus J, Prinsen MBW, Grobben Y, de Bitter TJJ, van Doornmalen AM, Melis JJTM, Uitdehaag JCM, Narumi Y, Kawase Y, de Roos JADM, Willemsen-Seegers N, Zaman GJR. Kooijman JJ, et al. Among authors: melis jjtm. Front Oncol. 2022 Sep 14;12:953013. doi: 10.3389/fonc.2022.953013. eCollection 2022. Front Oncol. 2022. PMID: 36185300 Free PMC article.
An adaptive randomized clinical trial in interstitial cystitis/bladder pain syndrome evaluating efficacy of ASP3652 and the relationship between disease characteristics and Hunner's lesions.
Houbiers JGA, van Till JWO, Kaper M, Yavuz Y, Martina RV, Cerneus D, Melis J, Stroosma O, Nickel JC, Hanno PM, Nordling J. Houbiers JGA, et al. Among authors: melis j. World J Urol. 2021 Jun;39(6):2065-2071. doi: 10.1007/s00345-020-03372-z. Epub 2020 Jul 30. World J Urol. 2021. PMID: 32734461 Clinical Trial.
46 results